RecruitingEarly Phase 1NCT05509257

Naltrexone Neuroimaging in Teens With Eating Disorders

Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders

Sponsor

Children's Mercy Hospital Kansas City

Enrollment

60 participants

Start Date

Sep 17, 2022

Study Type

INTERVENTIONAL

Conditions

Bulimia Nervosa Eating Disorders Binge Eating Purging (Eating Disorders)Anorexia Nervosa, Atypical

Summary

Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).

Eligibility

Min Age: 13 YearsMax Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Naltrexone and a drug called Placebo for people with anorexia nervosa, atypical, binge eating, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 13 Years to 21 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNaltrexone

Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.

DRUGPlacebo

Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.